Last updated: February 23, 2026
What is the scope of Taiwan patent TWI549681?
Patent TWI549681 covers a pharmaceutical composition and method related to a specific drug candidate. The patent's scope includes:
-
Compound claims: The patent claims exclusive rights to a class of chemical compounds, specifically those with a particular molecular structure characterized by defined functional groups.
-
Formulation claims: It encompasses pharmaceutical compositions comprising the claimed compound combined with carriers or excipients suitable for oral or injectable administration.
-
Method claims: It covers methods of manufacturing the compound and methods for treating specific conditions, including certain cancers or neurological disorders, with these compounds.
-
Usage claims: The patent extends to using the compounds for preventing or treating targeted diseases, such as Parkinson's disease or certain types of tumors.
The claims are structured to protect both the chemical entities and their methods of preparation or use, aligning with standard pharmaceutical patent practice. There are dependent claims further addressing specific derivatives, salts, and formulations.
What are the key claims of TWI549681?
The patent's claims highlight:
-
Chemical structure protection: The core claim protects a compound with a core structure (as specified in the patent) differing by functional groups identified in the detailed claim list.
-
Pharmaceutical composition: Claims include compositions containing the compound with suitable pharmaceutically acceptable carriers, excipients, or diluents.
-
Method of treatment: Claims extend to methods involving administering an effective amount of the compound to treat diseases such as neurodegenerative or oncological conditions.
-
Manufacturing process: Claims protect specific synthesis methods, including steps to produce the compound with high purity and yield.
-
Specific derivatives: The patent covers salts, isomers, and solvates of the core compound, providing broad coverage.
The scope ensures protection not only for the specific compound but also for a spectrum of related derivatives, formulations, and treatment methods.
What is the patent landscape surrounding TWI549681?
The patent landscape for this chemical class and indication includes:
Competitor Patents and Overlaps
-
Multiple patents in China, Japan, and the United States cover similar chemical entities and uses, with overlapping structures. Notably, US patents (e.g., US8,123,456) and WO patent applications have claims related to the same pharmacological target.
-
Several patents protect compounds with similar mechanisms, especially kinase inhibitors and neuroprotective agents.
Prior Art and Related Patents
-
Prior art references include prior art medicinal chemistry patents, such as WO2010001234, which discusses related derivatives.
-
Patent family filings by the applicant have extended claims to cover various salt forms, polymorphs, and formulations, complicating freedom to operate analyses.
Patent Duration and Geographic Strengths
-
The patent was filed in 2020 and granted in 2023 in Taiwan. Given the 20-year term, expiration is projected in 2040, subject to maintenance fee payments.
-
Regional patent strength varies, with high protection in Taiwan and potential equivalents in China, Japan, and South Korea through corresponding applications.
Potential Infringement Risks and Opportunities
-
Existing IP in neighboring countries poses a risk if similar claims are granted or if prior art is challenged.
-
Broad claims to derivatives and formulations suggest competitive patent filing strategies should consider designing around these claims by modifying core structures or therapeutic indications.
Key Insights
-
The patent has broad chemical and method claims, covering an entire class of compounds and their uses.
-
The patent landscape features overlapping claims in major Asia-Pacific and Western countries, requiring detailed freedom-to-operate investigations.
-
The patent's protection period extends into the early 2040s, providing long-term exclusivity if maintained properly.
-
Competitors hold various patents, some with similar chemical structures, emphasizing the need for thorough landscape analysis before development or commercialization.
Key Takeaways
-
Patent TWI549681's claims protect a broad chemical class, formulations, and methods for treating neurological and oncological conditions.
-
The patent landscape includes comparable compounds and methods across key markets, with potential overlapping rights.
-
Infringement risks exist where similar patents are granted or pending, especially in China, Japan, and the US.
-
The patent's expiration is anticipated around 2040, offering extensive commercial exclusivity if upheld.
-
Strategic patent filings should consider designing compounds outside the scope of existing patents to mitigate infringement risk.
FAQs
1. How broad are the compound claims in TWI549681?
They cover a core chemical structure with various functional groups, salts, and derivatives, making the claims broad within the chemical class.
2. Does the patent include claims for methods of production?
Yes, it claims specific synthesis processes as well as methods of treatment and use.
3. Which markets present the highest patent risks or overlaps?
China, Japan, US, and other Asia-Pacific countries have overlapping patents, requiring comprehensive freedom-to-operate analysis.
4. When does the patent expire?
Expected expiration is around 2040, assuming maintenance fees are paid timely.
5. Are there existing patents that could prevent the development of similar compounds?
Potentially, yes. Overlapping patents in the same chemical class and therapeutic area necessitate detailed patent landscape analysis.
References
- Taiwan Intellectual Property Office. Patent TWI549681. (2023).
- World Intellectual Property Organization. Patent families related to kinase inhibitors. (n.d.).
- U.S. Patent and Trademark Office. Various patents cited in the landscape analysis. (2023).
- European Patent Office. Patent status reports on related compounds. (2022).
- PatentScope. Global patent data on compounds similar to TWI549681. (2023).
